CANTOS: Less Cardiovascular Events with Canakinumab

A new analysis from the CANTOS trial shows that individuals who initially respond to canakinumab benefit the most from this new drug as regards cardiovascular events.

CANTOS: menos eventos cardiovasculares con Canakinumab

This sub-analysis presented at the American Heart Association 2017 Scientific Sessions and simultaneously published in the Lancet showed that the magnitude of the reduction in C-reactive protein following a single dose of canakinumab can identify the patients who will benefit the most from this therapy.


Read also: CANTOS: Anti-inflammatory Drug Canakinumab Seems to Reduce CV Events”.


Patients with a previous infarction and elevated levels of C-reactive protein who achieve a concentration of less than 2.0 mg/L after the administration of this monoclonal antibody that targets inflammatory pathways have a 25% reduction in the risk of infarction, stroke, and death when compared with individuals treated with a placebo.

 

Patients who, after drug administration, continue with C-reactive protein levels ≥2 mg/L do not experience any benefit from this treatment.

 

Canakinumab targets interleukin-1β, a cytokine that is involved in the inflammatory response and the development of atherothrombotic plaque, due to its potential procoagulant activity, promoting monocyte and leukocyte adhesion to endothelial cells, and promoting the release of growth factors for smooth-muscle cells.


Read also: NCDR ACTION Registry: Anticoagulated Patients with No Higher Risk of Bleeding in Emergency Procedures”.


The outcomes of CANTOS, including 10,061 patients, had been presented at the European Society of Cardiology Congress 2017 in Barcelona Now, at the AHA Congress, researchers presented the sub-analysis of biologic responders.

 

Original title: Relationship of C-Reactive Protein Reduction to Cardiovascular Event Reduction Following Treatment with Canakinumab: A Secondary Analysis from the CANTOS Randomized Controlled Trial.

Reference: Ridker PM et al. Lancet. 2017;Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....